All News     |   Press Releases     |   Newsletters     |   Blog

News

Read all of the latest news, press releases, newsletters, and blog posts. Choose a link above to filter by category.

    • 16 FEB 17
    • 0

    LATTICE BIOLOGICS CLOSES THIRD TRANCHE OF PRIVATE PLACEMENT ANNOUNCED ON JANUARY 19, 2017

    February 16th, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company“) is pleased to announce that it has closed the third tranche of its non-brokered private placement of Units of the Company (“Units“) announced on January 19, 2017 (the “Offering“). The Company has issued 658,260 Units at

    Read more →
    • 14 FEB 17
    • 0

    NOTICE OF LATTICE BIOLOGICS LTD. FIRST QUARTER 2017 FINANCIAL RESULTS CONFERENCE CALL

    Financial results to be released after market on Wednesday, March 1, 2017 February 14, 2017 – SCOTTSDALE – Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (the “Company“) announced today that it will release its first quarter 2017 financial results after market on Wednesday, March 1, 2017. Following this, Guy Cook, Chief Executive Officer, and Cheryl Farmer, Chief Financial

    Read more →
    • 30 JAN 17
    • 0

    LATTICE BIOLOGICS LTD. REPORTS FOURTH QUARTER AND YEAR END 2016 HIGHLIGHTS

    New core product sales increase 147% fourth quarter over fourth quarter January 30, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the fourth quarter and year ended September 30, 2016: Highlights: DBM Putty growth 620% Q4 2016 over Q4 2015 Acellular Dermal

    Read more →
    • 27 JAN 17
    • 0

    NOTICE OF LATTICE BIOLOGICS LTD. YEAR END 2016 FINANCIAL RESULTS CONFERENCE CALL

    Financial results to be released after market on Monday, January 30, 2017 January 27, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (the “Company”) announced today that it will release its year ended September 30, 2016 financial results after market on Monday, January 30, 2017. Following this, Guy Cook, Chief Executive

    Read more →
    • 26 JAN 17
    • 0

    LATTICE BIOLOGICS CLOSES SECOND TRANCHE OF PRIVATE PLACEMENT ANNOUNCED ON JANUARY 19, 2017

    NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES January 26, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: BLVKF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has closed the second tranche of the non-brokered private placement of Units of the Company (“Units”) announced on January

    Read more →
    • 24 JAN 17
    • 0

    LATTICE BIOLOGICS CLOSES FIRST TRANCHE OF PRIVATE PLACEMENT ANNOUNCED ON JANUARY 19, 2017

    NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES January 24, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: BLVKF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has closed the first tranche of the non-brokered private placement of Units of the Company (“Units”) announced on January

    Read more →
    • 19 JAN 17
    • 0

    LATTICE BIOLOGICS ANNOUNCES NEW PRIVATE PLACEMENT

    New funding raise of up to US$800,000 NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES January 19, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: BLVKF) (“Lattice Biologics” or the “Company”) is pleased to announce a new private placement of Units of the Company (“Units“) at a price of

    Read more →
    • 05 JAN 17
    • 0

    LATTICE BIOLOGICS ISSUES COMMON SHARES

    Additionally, Company announces closing of private placement Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (“Lattice Biologics” or the “Company“) is pleased to announce that it has obtained TSX Venture Exchange (“TSXV”) approval to issue 38,064 common shares (“Shares”) of the Company (“Shares“) to an individual as compensation for certain services rendered to the Company

    Read more →

Recent Events